Promethazine DM Cough Syrup: Clinical Guide to Promethazine Dextromethorphan Syrup

Promethazine DM Cough Syrup is a prescription oral solution combining promethazine hydrochloride, a first-generation antihistamine, with dextromethorphan hydrobromide, a non-opioid cough suppressant. It temporarily relieves dry cough and allergy-related upper respiratory symptoms without using an opioid. Although it is not a controlled substance, Promethazine DM Cough Syrup can cause significant drowsiness and serious drug interactions that require clinical oversight.

What Is Promethazine DM Cough Syrup?

Promethazine DM Cough Syrup is a prescription medication containing promethazine hydrochloride and dextromethorphan hydrobromide. It temporarily relieves dry cough and upper respiratory symptoms caused by allergies or the common cold. Unlike promethazine with codeine, it contains no opioid—but it causes significant drowsiness, interacts dangerously with alcohol and MAOIs, and requires a valid prescription and appropriate medical supervision.

Does Promethazine DM Have Codeine?

No. Promethazine DM Cough Syrup contains dextromethorphan hydrobromide, a non-opioid cough suppressant, instead of codeine. It is not a federally controlled substance, but it can still cause significant drowsiness, interact with other medications, and should only be used as prescribed by a licensed healthcare provider.

The absence of codeine does not eliminate clinical risk. Promethazine DM Cough Syrup contains a potent first-generation antihistamine that produces substantial CNS depression, anticholinergic effects, and serious drug interactions—making it a medication that demands the same clinical deliberateness as any prescription sedating agent.

Direct Answer: What Is the Promethazine DM Generic Name?

The generic name for Promethazine DM Cough Syrup is promethazine hydrochloride and dextromethorphan hydrobromide oral solution. Both active ingredients are available as FDA-approved generic formulations from multiple manufacturers. Generic products must meet the same regulatory standards for identity, potency, and bioequivalence as the reference listed drug under FDA oversight.

What Does Promethazine DM Treat?

Promethazine DM Cough Syrup is prescribed for the temporary relief of dry, non-productive cough, sneezing, runny nose, throat irritation, and other upper respiratory symptoms caused by allergies or the common cold. It relieves symptoms but does not treat the underlying illness.

It is not indicated for productive cough, lower respiratory disease, asthma, or COPD. Promethazine DM is a short-term symptomatic treatment, not a therapy for the condition producing the cough.

What Are Promethazine DM Prescription Requirements?

Promethazine DM Cough Syrup is a legend drug requiring a valid prescription from a licensed healthcare provider. It is not available over the counter in the United States.

It is not classified as a DEA controlled substance at the federal level. However, several states have enacted additional regulations restricting access to dextromethorphan-containing products—particularly for patients under 18—due to documented misuse of dextromethorphan at supratherapeutic doses. Clinicians should verify applicable state law when prescribing.

What Is the Difference Between Promethazine DM and Promethazine With Codeine?

Promethazine DM contains dextromethorphan, a non-opioid antitussive acting via NMDA and sigma-1 receptor mechanisms. Promethazine with codeine contains codeine phosphate, a Schedule V opioid antitussive acting via mu-opioid receptors.

The two formulations are not clinically interchangeable. They differ substantially in regulatory status, risk profile, and contraindications. Patients requiring opioid-level antitussive efficacy—those with severe, refractory cough—may not achieve equivalent relief with dextromethorphan. Formulation selection must be based on clinical indication and individualized risk-benefit assessment, not formulary convenience.

How Does Promethazine DM Work for Dry Cough?

Promethazine DM Cough Syrup acts through two simultaneous and pharmacologically distinct mechanisms.

Dextromethorphan suppresses the cough reflex centrally by antagonizing NMDA receptors in the medullary cough center and activating sigma-1 receptors, raising the neurological threshold required to initiate a cough. Promethazine blocks peripheral H1 histamine receptors, reducing histamine-mediated airway irritation that drives cough in allergic and upper respiratory contexts.

Combined, these mechanisms address both the central neurological drive and the peripheral mucosal trigger of dry, non-productive cough—a pharmacological rationale the combination achieves more completely than either agent alone.

What Are the Promethazine DM Interactions Clinicians Must Know?

The most clinically dangerous interactions with Promethazine DM Cough Syrup involve three categories:

MAOIs: Absolutely contraindicated. Concurrent use with monoamine oxidase inhibitors or within 14 days of MAOI discontinuation can cause serotonin syndrome—a life-threatening condition characterized by hyperthermia, neuromuscular instability, and autonomic dysfunction.

CNS depressants: Alcohol, benzodiazepines, opioids, muscle relaxants, and sedating antihistamines all potentiate promethazine’s CNS depression, increasing the risk of profound sedation and respiratory compromise.

Serotonergic agents: Dextromethorphan’s serotonergic activity creates additive risk with SSRIs, SNRIs, tricyclic antidepressants, triptans, and other serotonin-affecting medications. Promethazine DM interacts with MAO inhibitors, alcohol, opioids, benzodiazepines, sedatives, SSRIs, SNRIs, and other serotonergic medications—combinations that may increase the risk of excessive sedation, respiratory depression, or serotonin syndrome.

Can Promethazine DM Be Taken With Food?

Promethazine DM Cough Syrup may be taken with or without food. Food does not significantly alter the absorption of either active ingredient. For patients who experience nausea at initiation—a recognized side effect of promethazine at the outset of therapy—taking the medication with a small amount of food may reduce gastric irritation without compromising therapeutic effect.

Is Promethazine DM Addictive?

Promethazine DM Cough Syrup does not contain an opioid and is not classified as a DEA controlled substance. Physical dependence of the type associated with opioid or benzodiazepine therapy is not an expected consequence of therapeutic use.

However, dextromethorphan carries documented recreational misuse potential at supratherapeutic doses—producing dissociative effects through NMDA antagonism that have driven misuse primarily among adolescents. Therapeutic use at prescribed doses under medical supervision does not produce addiction in the clinical sense, but prescribers should remain alert to signs of misuse, particularly in adolescent patients.

What Should You Avoid While Taking Promethazine DM?

Patients taking Promethazine DM Cough Syrup should avoid:

• Alcohol—synergistic CNS depression increases sedation and respiratory depression risk
• MAOIs—absolute contraindication due to serotonin syndrome risk
• Driving or operating heavy machinery—psychomotor impairment is clinically significant and may persist beyond the perceived duration of drug effect
• Other sedating medications including benzodiazepines, opioids, sleep aids, and sedating antihistamines
• Serotonergic medications without explicit clinical review and monitoring plan
• Unsupervised dose escalation—dextromethorphan produces dissociative effects at supratherapeutic doses

Can Promethazine DM Affect Driving?

Yes. Promethazine DM Cough Syrup significantly impairs cognitive function, reaction time, and psychomotor performance through promethazine’s CNS depressant activity. The FDA and prescribing information for promethazine-containing products advise against driving or operating dangerous machinery during therapy.

This restriction applies from the first dose, throughout the entire course of treatment, and cannot be self-assessed based on subjective feelings of alertness—which are an unreliable indicator of actual psychomotor impairment under antihistamine sedation. Promethazine’s elimination half-life of 10 to 19 hours means impairment from evening doses may persist into the following morning.

Promethazine DM Cough Syrup at a Glance

Promethazine DM Cough Syrup is a prescription oral solution combining promethazine hydrochloride, a first-generation antihistamine, with dextromethorphan hydrobromide, a non-opioid cough suppressant. It is indicated for temporary relief of dry cough and upper respiratory symptoms associated with allergies or the common cold.

The medication contains no opioid and is not a federally controlled substance, but it produces significant sedation, carries a pediatric contraindication in children under 2 years, and interacts dangerously with MAOIs, alcohol, and CNS depressants. Safe use requires prescription authorization, calibrated dosing, patient education, and awareness of serotonin syndrome risk when combined with serotonergic medications.

Key Clinical Facts: Promethazine DM Cough Syrup

Key Takeaways: What Clinicians and Patients Should Know

• Promethazine DM Cough Syrup contains no opioid and is not a DEA controlled substance—but the absence of codeine does not eliminate serious clinical risk from sedation, anticholinergic effects, and drug interactions
• The combination of promethazine and dextromethorphan addresses both central cough reflex suppression and histamine-mediated peripheral airway irritation—a dual mechanism neither agent alone can fully replicate
• MAOI combination with Promethazine DM Cough Syrup is absolutely contraindicated; the risk of serotonin syndrome is pharmacologically predictable and potentially fatal
• Dextromethorphan’s documented misuse potential at supratherapeutic doses has prompted state-level restrictions on access for patients under 18
• Promethazine DM Cough Syrup is a short-term symptomatic treatment; it does not address the underlying cause of cough and should not substitute for clinical evaluation of persistent or unexplained cough
• Calibrated dosing with an oral dosing syringe is a patient safety requirement—household spoons deliver unacceptable dosing variability
• Promethazine DM is not clinically interchangeable with promethazine with codeine; formulation selection must be based on clinical indication and individualized assessment

Introduction: Why Promethazine DM Cough Syrup Requires Informed Clinical Judgment

Promethazine DM Cough Syrup presents a clinical paradox that practitioners encounter regularly: a medication that appears straightforward—non-opioid, non-controlled, widely prescribed—but carries a pharmacological complexity that its scheduling status does not fully communicate.

The absence of codeine removes opioid-associated risks: addiction potential, DEA scheduling requirements, the pediatric contraindication in children under 12 that now applies to all codeine-containing antitussives, and the CYP2D6 ultra-rapid metabolizer risk that has made promethazine with codeine a subject of ongoing regulatory scrutiny. These are meaningful clinical distinctions.

What the absence of codeine does not remove is the pharmacological weight of promethazine itself. As a first-generation phenothiazine antihistamine with potent H1 receptor antagonism, significant dopamine receptor blockade, and meaningful anticholinergic activity, promethazine produces sedation that is both clinically useful and genuinely hazardous when combined with alcohol, benzodiazepines, or other CNS depressants. It carries a documented risk of neuroleptic malignant syndrome. It prolongs the QT interval. And in patients under 2 years—and in those with certain respiratory conditions regardless of age—it can contribute to respiratory compromise that is indistinguishable in consequence from opioid-induced depression.

Dextromethorphan, meanwhile, is not the pharmacologically inert compound that its over-the-counter availability in other formulations might suggest. At supratherapeutic doses, it produces dissociative effects through NMDA antagonism that have driven documented recreational misuse—particularly among adolescents. At therapeutic doses, its serotonergic activity creates a clinically significant interaction risk with MAOIs and other serotonin-affecting medications capable of producing life-threatening serotonin syndrome.

This guide addresses the mechanism, indications, dosing standards, drug interactions, side effect profile, comparative pharmacology, and clinical decision framework for Promethazine DM Cough Syrup. It is written for clinicians making prescribing decisions, patients seeking informed understanding of their prescription, and healthcare decision-makers evaluating the evidence base for non-opioid antitussive combination therapy.

What Is Promethazine DM Cough Syrup?

Promethazine DM Cough Syrup is a prescription combination oral solution containing two pharmacologically distinct active agents: promethazine hydrochloride, a phenothiazine-class first-generation antihistamine, and dextromethorphan hydrobromide, a synthetic morphinan derivative that functions as a non-opioid antitussive.

The standard formulation delivers 6.25 mg of promethazine hydrochloride and 15 mg of dextromethorphan hydrobromide per 5 mL of oral solution. This fixed-ratio combination cannot be titrated independently—adjusting dose requires changing the administered volume, which simultaneously alters exposure to both active ingredients.

Promethazine DM Cough Syrup is not classified as a federally controlled substance under DEA scheduling. It requires a valid prescription as a legend drug, but unlike promethazine with codeine, it carries no Schedule V designation and does not trigger mandatory Prescription Drug Monitoring Program (PDMP) consultation in most jurisdictions. This regulatory distinction, while administratively meaningful, does not diminish the clinical responsibility associated with prescribing a potent sedating antihistamine in combination with a serotonergic antitussive that has documented misuse potential.

No branded formulation of Promethazine DM Cough Syrup remains commercially available in the United States. Multiple FDA-approved generic manufacturers produce bioequivalent oral solutions that must meet identical regulatory standards for potency, purity, and sterility as confirmed through FDA DailyMed labeling.

Clinical bottom line: Promethazine DM Cough Syrup is a short-term symptomatic antitussive for dry, non-productive cough. It does not treat the underlying pathology producing the cough. Every prescription requires a clinical diagnosis, patient education on sedation and drug interactions, and a defined short-term treatment plan with a scheduled reassessment point.

Promethazine DM Cough Syrup Uses and Clinical Indications

What Does Promethazine DM Treat?

According to FDA prescribing information, Promethazine DM Cough Syrup is indicated for the temporary relief of cough and upper respiratory symptoms—including nasal congestion, throat irritation, sneezing, and runny nose—associated with allergy or the common cold.

The indication is deliberately narrow:

• Temporary relief—Promethazine DM is not appropriate for maintenance antitussive therapy or chronic cough management
• Dry, non-productive cough—not indicated for productive cough, lower respiratory disease, asthma exacerbation, or COPD
• Upper respiratory origin—not a first-line treatment for cough arising from cardiac disease, gastroesophageal reflux, medication-induced cough (ACE inhibitors), or pulmonary malignancy

Clinicians must evaluate the etiology of cough before prescribing Promethazine DM Cough Syrup. Suppressing a cough of unknown or serious origin with any antitussive risks masking clinical findings that would otherwise prompt timely diagnostic workup.

Appropriate Clinical Contexts for Promethazine DM

Dry cough associated with viral upper respiratory infection: The primary evidence-based indication. Promethazine DM for dry cough during the acute phase of viral URI provides central cough reflex suppression alongside antihistaminergic relief of associated nasal symptoms.

Allergic rhinitis with cough component: Promethazine’s H1 receptor antagonism addresses the histamine-mediated mechanism driving cough in allergic contexts—post-nasal drip, mucosal irritation, airway hypersensitivity—while dextromethorphan suppresses the central cough reflex directly.

Post-nasal drip-associated cough: Post-nasal drip secondary to allergic or non-allergic rhinitis generates cough through continuous mucosal irritation of the posterior pharynx. Promethazine’s combined antihistaminergic and anticholinergic activity reduces secretion volume and inflammatory stimulus while dextromethorphan raises the cough threshold centrally.

When Promethazine DM Cough Syrup Is Not Appropriate

• Children under 2 years of age—absolute contraindication
• Patients with lower respiratory disease including asthma exacerbation or COPD flare
• Patients with obstructive sleep apnea—sedation risk is substantially elevated
• Patients currently using or who have used MAOIs within 14 days—absolute contraindication due to serotonin syndrome risk
• Patients with productive cough where expectoration is clinically important—cough suppression may impair secretion clearance
• Cough of unknown or undiagnosed etiology—antitussive suppression before diagnosis constitutes a diagnostic delay risk

Promethazine DM Mechanism of Action: Dual Pharmacology

Dextromethorphan: Central Non-Opioid Cough Suppression

Dextromethorphan hydrobromide is a synthetic morphinan compound that does not bind clinically to opioid receptors at therapeutic doses. Its antitussive mechanism operates through two distinct molecular targets:

NMDA receptor antagonism: Dextromethorphan blocks N-methyl-D-aspartate receptors in the medullary cough center, reducing excitatory glutamatergic signaling that drives cough reflex activation. This mechanism—shared structurally with ketamine and memantine—is responsible for dextromethorphan’s dissociative properties at supratherapeutic doses.

Sigma-1 receptor activation: Dextromethorphan activates sigma-1 receptors in the brainstem, contributing additional modulation of cough reflex pathways through mechanisms under active pharmacological investigation.

Dextromethorphan does not suppress respiratory drive at therapeutic antitussive doses. This distinguishes it pharmacologically from codeine and other opioid antitussives and is central to its safety profile in patients for whom respiratory depression risk is a concern.

Promethazine: H1 Antagonism, Dopamine Blockade, and Anticholinergic Activity

Promethazine hydrochloride exerts its clinical effects through three simultaneous receptor mechanisms:

H1 histamine receptor antagonism: Competitive blockade of peripheral H1 receptors reduces histamine-mediated bronchoconstriction, mucosal edema, and secretion that drive cough in allergic and post-viral respiratory contexts.

Dopamine receptor blockade: D2 receptor antagonism in the chemoreceptor trigger zone produces antiemetic activity. The same dopamine receptor blockade also produces sedation and carries risk of extrapyramidal adverse effects including acute dystonia.

Anticholinergic activity: Muscarinic receptor blockade reduces secretory activity in nasal and bronchial mucosa, drying post-nasal secretions that contribute to cough. This mechanism also produces dry mouth, urinary retention, blurred vision, constipation, and—in susceptible patients—cognitive impairment and delirium.

Why the Combination Matters Clinically

The pharmacological rationale for combining promethazine with dextromethorphan in Promethazine DM Cough Syrup is mechanistic, not simply additive. Dextromethorphan targets the central neurological drive to cough; promethazine targets the peripheral histaminergic and cholinergic mechanisms that generate the airway irritation initiating that drive. The combination addresses both dimensions of dry cough simultaneously—a pharmacological scope neither agent alone can fully replicate in patients where both peripheral irritation and central hypersensitivity contribute to symptom burden.

Expert take: Dextromethorphan’s non-opioid status is pharmacologically genuine but clinically incomplete as a safety description. At therapeutic doses, it is neither an opioid nor a respiratory depressant. But its NMDA antagonism produces documented dissociative effects at supratherapeutic doses, its serotonergic activity creates meaningful drug interaction risk, and its combination with a sedating phenothiazine antihistamine produces a CNS depressant load that patients and some clinicians underestimate. The prescription status of Promethazine DM Cough Syrup exists precisely because this combination requires clinical supervision that over-the-counter availability cannot provide.

Promethazine DM Dosage: Clinical Standards

Standard Adult Dosage

The standard formulation of Promethazine DM Cough Syrup delivers 6.25 mg promethazine hydrochloride and 15 mg dextromethorphan hydrobromide per 5 mL.

Adult dosing: 5 mL every 4 to 6 hours as needed for symptom relief, not to exceed 30 mL in a 24-hour period.

Duration of therapy: Promethazine DM Cough Syrup is indicated for short-term use. Prescriptions extending beyond 5 to 7 days without clinical reassessment are not appropriate. Persistent cough beyond this timeframe requires re-evaluation for underlying pathology—including chronic cough causes such as GERD, ACE inhibitor use, post-nasal drip syndrome, or occult pulmonary disease—rather than continued antitussive suppression.

Pediatric Dosing

Children under 2 years: Absolutely contraindicated. The FDA black box warning for promethazine explicitly prohibits use in this age group due to risk of fatal respiratory depression.

Children 2 to under 6 years: Use is not generally recommended. If prescribed, dosing must be individualized by the prescribing clinician with explicit caution and close monitoring.

Children 6 to under 12 years: Typically 2.5 mL every 4 to 6 hours as needed; maximum 15 mL per 24 hours.

Children 12 years and older: Adult dosing applies.

Promethazine DM Dosage Precision: A Patient Safety Requirement

Promethazine DM Cough Syrup must be measured exclusively with a calibrated oral dosing syringe or graduated medication cup. Household spoons deliver volumes that are systematically inaccurate, producing dose deviations of up to 50% or more above or below the intended amount.

For a medication combining a sedating antihistamine with a serotonergic antitussive, dosing imprecision is a patient safety failure. Every prescription for Promethazine DM Cough Syrup should include explicit instruction to use only a calibrated measuring device. Pharmacists should routinely dispense a calibrated oral dosing syringe with every fill as standard clinical practice.

Promethazine DM Side Effects: Clinical Monitoring Framework

Common Adverse Effects

Promethazine DM side effects reflect the simultaneous pharmacological activity of both active ingredients—H1 antagonism, dopamine blockade, anticholinergic activity, and NMDA receptor modulation operating in parallel.

Central nervous system:

• Sedation and drowsiness—the most consistently reported and clinically significant adverse effect; driven primarily by promethazine’s H1 and dopamine receptor antagonism
• Dizziness and impaired coordination
• Cognitive dulling and psychomotor slowing
• Confusion, particularly in elderly patients where anticholinergic burden accumulates

Anticholinergic effects:

• Dry mouth
• Blurred vision
• Urinary retention, particularly in older males with benign prostatic hyperplasia
• Constipation and reduced gastrointestinal motility

Other:

• Mild nausea at initiation—typically transient and offset by promethazine’s antiemetic activity
• Photosensitivity throughout the course of therapy
• Pruritus (rare)

Serious Adverse Effects Requiring Immediate Response

Respiratory depression: Promethazine DM does not contain an opioid and dextromethorphan does not suppress respiratory drive at therapeutic doses. However, promethazine’s sedative CNS depression can contribute to respiratory compromise—particularly in children under 2, patients with obstructive sleep apnea, and those who have concurrently consumed alcohol or other CNS depressants.

Serotonin syndrome: Dextromethorphan’s serotonergic activity creates a clinically documented risk of serotonin syndrome when combined with MAOIs, SSRIs, SNRIs, tricyclic antidepressants, or triptans. Serotonin syndrome presents with a triad of neuromuscular abnormalities (clonus, tremor, hyperreflexia), autonomic instability (hyperthermia, tachycardia, diaphoresis), and altered mental status. It ranges from mild to life-threatening and requires prompt discontinuation of causative agents and emergency evaluation in severe cases.

Neuroleptic Malignant Syndrome (NMS): Promethazine’s dopamine receptor antagonism creates a recognized risk of NMS—characterized by hyperthermia, severe muscular rigidity, altered consciousness, and autonomic instability. While rare, NMS is potentially fatal and requires immediate discontinuation and emergency evaluation.

QT prolongation: Promethazine has documented QT-prolonging potential. Patients with baseline QT prolongation, hypokalemia, hypomagnesemia, or concurrent QT-prolonging medications face elevated risk of potentially fatal ventricular arrhythmia.

Acute dystonic reactions: Promethazine’s dopamine receptor blockade can produce acute dystonia—involuntary muscle contractions, oculogyric crisis, or torticollis—particularly in younger patients and at higher doses.

Expert take: The most clinically underappreciated risks of Promethazine DM Cough Syrup are not the side effects patients anticipate—drowsiness and dry mouth—but the serious adverse effects they do not: serotonin syndrome from concurrent serotonergic medications, neuroleptic malignant syndrome from dopamine receptor blockade, and QT prolongation from promethazine’s cardiac effects. Each risk is pharmacologically predictable, clinically preventable, and capable of producing a life-threatening outcome in a patient who believed they were taking a routine cough remedy.

When to Seek Emergency Medical Care

When to Call 911

Call emergency services immediately if a patient taking Promethazine DM Cough Syrup experiences any of the following:

• Breathing that is slow, labored, or has stopped
• Blue, gray, or pale discoloration of the lips, fingernails, or skin
• Loss of consciousness or inability to be awakened
• Seizure activity
• Signs of serotonin syndrome: sudden agitation, confusion, rapid heart rate, high fever, twitching, or severe muscle stiffness
• Severe allergic reaction: hives, throat tightening, facial swelling, or difficulty swallowing
• Suspected overdose from any cause

Overdose Symptoms

Promethazine DM Cough Syrup overdose may present with:

• Extreme drowsiness or inability to rouse
• Profound confusion or disorientation
• Slow, shallow, or irregular breathing
• Hallucinations (dextromethorphan toxicity at high doses)
• Muscle rigidity or seizures
• Irregular heartbeat
• Loss of consciousness or coma

Overdose requires immediate emergency medical evaluation. Poison Control (1-800-222-1222 in the United States) can provide guidance while emergency services are en route. There is no specific antidote for promethazine or dextromethorphan overdose; management is supportive and symptom-directed.

Promethazine DM Interactions: Complete Clinical Reference

MAOIs: The Most Critical Contraindication

Concurrent use of Promethazine DM Cough Syrup with monoamine oxidase inhibitors—or within 14 days of MAOI discontinuation—is absolutely contraindicated. MAOIs prevent the enzymatic breakdown of serotonin; dextromethorphan’s serotonin reuptake inhibition and serotonergic activity combined with MAOI-mediated serotonin accumulation can precipitate serotonin syndrome within hours of administration.

This interaction is not dose-dependent at the low end. Even therapeutic doses of dextromethorphan in a patient taking an MAOI can produce serotonin syndrome. No clinical justification exists for this combination.

CNS Depressant Interactions

Serotonergic Drug Interactions

CYP2D6 Interactions

Dextromethorphan is primarily metabolized by CYP2D6. Inhibitors of this enzyme—including fluoxetine, paroxetine, bupropion, and quinidine—substantially reduce dextromethorphan clearance, increasing plasma concentrations and the risk of adverse effects including dizziness, dissociation, and enhanced serotonergic activity.

In patients who are CYP2D6 poor metabolizers, dextromethorphan accumulation at standard doses may produce unexpectedly pronounced effects even without concurrent CYP2D6-inhibiting medications.

QT-Prolonging Agents

Promethazine’s intrinsic QT-prolonging potential is additive with other QT-prolonging medications—including certain antiarrhythmics, antipsychotics, fluoroquinolone antibiotics, and azole antifungals. Patients receiving multiple QT-prolonging agents require baseline and monitoring electrocardiography.

Clinical requirement: Complete medication reconciliation—including prescription medications, over-the-counter products, herbal supplements, and alcohol—must be completed before every Promethazine DM Cough Syrup prescription is written and dispensed.

Promethazine DM vs Codeine Formulations: Definitive Clinical Comparison

The distinction between Promethazine DM and promethazine with codeine is not simply the presence or absence of a controlled substance. It reflects fundamentally different pharmacological mechanisms, risk profiles, regulatory frameworks, and clinical indications.

Expert take: Promethazine DM and promethazine with codeine are not interchangeable antitussive options at different risk levels—they are pharmacologically distinct agents with different mechanisms, contraindications, interaction profiles, and clinical indications. Selecting between them requires understanding what is driving the cough, what risks the patient carries, and what the regulatory context requires. Formulation selection is a clinical decision, not a formulary convenience.

Promethazine DM vs Benzonatate

Benzonatate is a non-opioid, non-antihistamine antitussive that acts peripherally by anesthetizing pulmonary stretch receptors, reducing the afferent signal that triggers the cough reflex.

Clinical distinction: Benzonatate is preferred when allergic or histaminergic components are absent and when sedation must be minimized. Promethazine DM Cough Syrup is pharmacologically better suited to dry cough with a concurrent allergic or histaminergic driver—where promethazine’s H1 antagonism adds therapeutic value that benzonatate cannot provide.

Pediatric Safety: Promethazine DM Age Restrictions

The Under-2 Contraindication

Promethazine is absolutely contraindicated in children under 2 years of age. The FDA’s black box warning is explicit: promethazine can cause fatal respiratory depression in very young children, and no safe dose has been established for this age group.

Infant respiratory control centers are substantially less mature than those of older children and adults, making them disproportionately sensitive to any agent that depresses CNS activity. The narrow therapeutic margin in infants leaves virtually no buffer between an antihistaminergic sedative dose and a respiratory-compromising dose.

Ages 2 to Under 6: High Caution Required

For children aged 2 to under 6, Promethazine DM Cough Syrup should be prescribed only when clearly necessary and with exceptional caution. Caregivers must be educated regarding respiratory depression warning signs and instructed to seek immediate emergency care if the child cannot be aroused or shows any signs of labored or inadequate breathing.

The Dextromethorphan Pediatric Misuse Context

Dextromethorphan’s recreational misuse—exploiting its NMDA antagonist dissociative properties at supratherapeutic doses—is disproportionately prevalent among adolescents. The National Institute on Drug Abuse (NIDA) documents dextromethorphan as among the most commonly misused OTC ingredients among teens. Multiple states have enacted laws restricting over-the-counter sale of dextromethorphan-containing products to individuals under 18. While Promethazine DM Cough Syrup is prescription-only, this context is relevant to prescribing decisions and quantity limits when treating adolescent patients.

Pregnancy and Breastfeeding

Pregnancy

Promethazine DM Cough Syrup should be used during pregnancy only when clearly necessary and when the clinical benefit to the mother outweighs potential fetal risk. Neither active ingredient has a well-established safety record in pregnancy through controlled trials.

Promethazine crosses the placental barrier and has been associated with neonatal effects including sedation and extrapyramidal symptoms in infants born to mothers who received promethazine near the time of delivery. Dextromethorphan data in human pregnancy are limited; animal studies do not suggest teratogenicity at therapeutic doses, but human evidence is insufficient to draw definitive conclusions.

Pregnant patients requiring antitussive therapy should discuss the specific risk-benefit profile of Promethazine DM Cough Syrup with their obstetric provider before use. The National Library of Medicine LactMed database provides regularly updated guidance on medication use during pregnancy and lactation.

Breastfeeding

Both promethazine and dextromethorphan are present in human breast milk in limited quantities. The clinical significance of infant exposure through breast milk is not fully characterized.

Promethazine’s sedative and anticholinergic activity—and its documented association with infant respiratory depression at higher exposures—warrants caution. Breastfeeding mothers who require Promethazine DM Cough Syrup should discuss the timing of doses relative to breastfeeding and the clinical necessity of therapy with their healthcare provider. The shortest course at the lowest effective dose minimizes infant exposure.

Promethazine DM for Dry Cough: Evidence and Clinical Context

The Evidence Basis

The evidence supporting dextromethorphan for acute dry cough in adults is modest and contested. A 2014 Cochrane systematic review of antitussives for acute cough found that evidence for dextromethorphan’s superiority over placebo was limited by small sample sizes, heterogeneous cough etiologies, and poorly standardized outcome measures.

Evidence for the promethazine-dextromethorphan combination specifically is more limited still. The pharmacological rationale for the combination—dual targeting of central cough reflex and peripheral histaminergic irritation—is mechanistically sound but has not been evaluated in large, methodologically rigorous randomized controlled trials.

The 2006 CHEST guideline on cough diagnosis and management noted that first-generation antihistamines demonstrate modest benefit in acute cough associated with the common cold, attributed primarily to their anticholinergic reduction of post-nasal drip rather than direct antitussive activity.

Clinical Positioning

Promethazine DM Cough Syrup occupies a specific clinical niche: patients with dry, non-productive cough producing functional impairment—particularly sleep disruption—where a histaminergic or allergic component is present and where a non-opioid approach is clinically preferred or indicated.

It is not appropriate as a first-line antitussive for all acute cough presentations and is not a substitute for evaluation of cough that is persistent, progressive, associated with systemic symptoms, or of unknown etiology.

Patient Selection, Safe Use, and Monitoring

Appropriate Candidates for Promethazine DM Cough Syrup

Promethazine DM Cough Syrup is appropriate for patients who:

• Are 2 years of age or older without significant respiratory compromise
• Present with dry, non-productive cough producing functional impairment
• Have an identified clinical context consistent with the indication—viral URI or allergic rhinitis
• Have undergone complete medication reconciliation confirming no MAOI use or high-risk serotonergic interactions
• Can be educated regarding sedation, driving restrictions, alcohol avoidance, and correct dosing technique
• Have a defined short-term treatment plan with a scheduled reassessment point

Safe Use Checklist: Before Prescribing Promethazine DM Cough Syrup

•  Confirmed indication: dry, non-productive cough with upper respiratory or allergic origin
•  Age confirmed: 2 years or older
•  MAOI use excluded: no current use and no use within 14 days
•  Serotonergic medication review completed
•  CNS depressant co-medications identified and risk-benefit evaluated
•  QT prolongation risk assessed
•  Alcohol use history obtained and counseling provided
•  Calibrated oral dosing syringe to be dispensed with prescription
•  Patient education completed: sedation, driving, alcohol, interaction warning signs
•  Duration of therapy specified; reassessment scheduled

Special Populations

Elderly patients: Promethazine’s anticholinergic and sedative effects are disproportionately pronounced in older adults. The American Geriatrics Society Beers Criteria lists first-generation antihistamines as medications to avoid in patients 65 and older due to anticholinergic burden, cognitive effects, and fall risk. Prescribing Promethazine DM Cough Syrup in elderly patients requires explicit risk-benefit justification and enhanced monitoring.

Patients with hepatic impairment: Both promethazine and dextromethorphan undergo hepatic metabolism. Impaired hepatic function prolongs drug exposure and amplifies adverse effect risk, particularly sedation and serotonergic activity from dextromethorphan accumulation.

CYP2D6 poor metabolizers: Patients with reduced CYP2D6 activity metabolize dextromethorphan slowly, producing higher plasma concentrations at standard doses—even without concurrent CYP2D6-inhibiting medications. These patients face elevated risk of dextromethorphan-related adverse effects including dizziness, dissociation, and serotonergic activity.

Safe Storage, Disposal, and Driving Guidance

Safe Storage

Promethazine DM Cough Syrup must be stored at controlled room temperature—typically 59°F to 77°F (15°C to 25°C)—in the original prescription container, away from heat, light, and moisture. Refrigeration is not required and may alter the viscosity of the oral solution.

The medication must be kept out of reach of children at all times. Promethazine is absolutely contraindicated in children under 2, and dextromethorphan is a documented target for adolescent misuse. Unsecured storage represents a risk to both categories of vulnerable household members.

Do not use Promethazine DM Cough Syrup beyond the printed expiration date. Expired medication should be disposed of promptly.

Missed Dose Guidance

Because Promethazine DM Cough Syrup is typically prescribed on an as-needed basis, missed dose scenarios are uncommon. If a patient is using it on a regular schedule and misses a dose, they should take it when remembered—unless it is nearly time for the next dose, in which case the missed dose should be skipped.

Patients must never double a dose to compensate for a missed one. The combined sedative burden of two doses taken in close succession can produce profound CNS depression, particularly in elderly patients or those with respiratory conditions.

Driving and Operating Machinery

Promethazine DM Cough Syrup significantly impairs cognitive function, reaction time, and psychomotor performance. Patients must not drive or operate heavy machinery while taking this medication.

This restriction applies from the first dose throughout the entire course of treatment. Promethazine’s elimination half-life of 10 to 19 hours means that sedative impairment from evening doses may persist into the following morning—even when patients feel subjectively rested and alert. Subjective feelings of alertness are an unreliable indicator of actual psychomotor function under antihistamine sedation, a discrepancy documented in antihistamine pharmacodynamic research.

Safe Disposal

Unused Promethazine DM Cough Syrup should be disposed of through a DEA-authorized drug take-back program. If take-back is unavailable, the FDA recommends mixing the liquid with an unpalatable substance, sealing it in a container, and disposing in household trash—removing or obscuring all prescription label information before disposal.

Evidence Summary: What the Research Shows

Evidence Quality

What the Evidence Confirms

The evidence base for Promethazine DM Cough Syrup supports its use as a short-term symptomatic treatment for dry cough in adult patients with an identified allergic or viral upper respiratory etiology. The pharmacological rationale for the combination is mechanistically sound; the clinical evidence for superiority over single-agent alternatives or placebo is more limited.

The evidence for harm is substantially clearer: serotonin syndrome risk with concurrent serotonergic agents is pharmacologically inevitable; pediatric respiratory depression risk from promethazine in children under 2 is documented in fatality reports; and dextromethorphan misuse potential at supratherapeutic doses is well-established in epidemiological and pharmacological literature reviewed by NIDA.

Frequently Asked Questions: Promethazine DM Cough Syrup

What is Promethazine DM Cough Syrup used for?

Promethazine DM Cough Syrup is prescribed for the temporary relief of dry, non-productive cough, throat irritation, nasal congestion, sneezing, and runny nose associated with allergies or the common cold. It relieves symptoms but does not treat the underlying cause of cough.

Does Promethazine DM have codeine?

No. Promethazine DM Cough Syrup contains dextromethorphan hydrobromide, a non-opioid cough suppressant, instead of codeine. It is not a federally controlled substance, but it can still cause significant drowsiness, interact with other medications, and should only be used as prescribed by a licensed healthcare provider.

What are the most common Promethazine DM side effects?

The most common Promethazine DM side effects include drowsiness, dizziness, dry mouth, blurred vision, constipation, and urinary retention. Sedation is the most clinically significant and consistently reported adverse effect. Serious adverse effects—including serotonin syndrome, neuroleptic malignant syndrome, and QT prolongation—require immediate clinical evaluation and discontinuation.

Can you buy Promethazine DM over the counter?

No. Promethazine DM is a prescription-only legend drug in the United States. A valid prescription from a licensed healthcare provider is required. Several states have also enacted additional restrictions on dextromethorphan-containing products for patients under 18.

Can Promethazine DM be taken with alcohol?

No. Alcohol potentiates the CNS depressant effects of both active ingredients in Promethazine DM Cough Syrup, producing additive sedation, impaired coordination, and increased risk of respiratory depression. Alcohol must be avoided for the entire duration of therapy—not only immediately before or after dosing.

How long does Promethazine DM take to work?

Most patients begin experiencing symptom relief within 15 to 30 minutes of oral administration. Cough suppression and antihistaminergic symptom relief typically persist for 4 to 6 hours per dose. Sedative effects from promethazine may persist considerably longer due to its elimination half-life of approximately 10 to 19 hours.

What medications interact with Promethazine DM?

The most critical interactions involve MAOIs (absolutely contraindicated due to serotonin syndrome risk), alcohol and CNS depressants (additive sedation and respiratory depression), serotonergic agents including SSRIs and SNRIs (serotonin syndrome risk), CYP2D6 inhibitors (dextromethorphan accumulation), and QT-prolonging agents (additive cardiac risk from promethazine). Complete medication reconciliation is required before prescribing.

What is the difference between Promethazine DM and Promethazine with Codeine?

Promethazine DM contains dextromethorphan, a non-opioid antitussive acting via NMDA and sigma-1 receptor mechanisms. Promethazine with codeine contains codeine phosphate, a Schedule V opioid antitussive acting via mu-opioid receptors. The two formulations are not clinically interchangeable, differ substantially in regulatory status, risk profiles, and contraindications, and require independent clinical evaluation for appropriate patient selection.

Clinical Pearls: Key Takeaways for Practice

Clinical Pearl 1: The most dangerous interaction with Promethazine DM Cough Syrup is not alcohol—it is MAOIs. Serotonin syndrome from dextromethorphan in a patient taking an MAOI is pharmacologically predictable, does not require supratherapeutic doses, and can produce a life-threatening outcome from a prescription that appeared routine. MAOI status must be confirmed—not assumed negative—before every Promethazine DM prescription is written.

Clinical Pearl 2: Dextromethorphan’s non-opioid status does not make Promethazine DM Cough Syrup a low-risk prescription. Dextromethorphan is a serotonergic compound with documented NMDA-mediated dissociative effects at high doses, meaningful CYP2D6-dependent pharmacokinetic variability, and established recreational misuse potential among adolescents. Clinical supervision of its use is not a formality—it is a pharmacological necessity.

Clinical Pearl 3: Promethazine’s 10 to 19 hour elimination half-life means that sedative impairment from Promethazine DM Cough Syrup persists substantially beyond the 4 to 6 hour symptomatic duration. Patients who dose in the evening may experience meaningful psychomotor impairment the following morning. This duration of effect must be explicitly communicated—not assumed self-evident—in every patient counseling encounter.

Clinical Pearl 4: The American Geriatrics Society Beers Criteria lists first-generation antihistamines as potentially inappropriate in patients 65 and older. Prescribing Promethazine DM Cough Syrup in elderly patients requires explicit risk-benefit documentation. Falls, delirium, urinary retention, and constipation from anticholinergic burden are clinically meaningful harms in this population—not acceptable side effects of routine antitussive therapy.

Clinical Pearl 5: Calibrated dosing of Promethazine DM Cough Syrup is a clinical standard, not a preference. Household spoons deliver volumes that deviate significantly from the intended dose. A calibrated oral dosing syringe dispensed at the time of prescription fill is the pharmacist’s professional responsibility and the clinician’s prescribing expectation. Every Promethazine DM prescription should generate this standard.

References

• FDA Prescribing Information: Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution
• FDA DailyMed: Promethazine DM Labeling
• FDA Drug Safety Communication: Promethazine and Children Under 2 Years
• FDA Drug Safety Communication: Codeine Contraindication in Children Under 12 (2013)
• Irwin RS, et al. Diagnosis and Management of Cough Executive Summary: CHEST Guideline and Expert Panel Report. CHEST. 2006;129(1 Suppl):1S–23S.
• Smith SM, et al. Over-the-Counter (OTC) Medications for Acute Cough in Children and Adults in Community Settings. Cochrane Database of Systematic Reviews. 2014;(11):CD001831.
• Boyer EW, Shannon M. The Serotonin Syndrome. New England Journal of Medicine. 2005;352(11):1112–1120.
• American Geriatrics Society 2023 Beers Criteria Update
• National Institute on Drug Abuse: Prescription and OTC Drug Misuse
• National Library of Medicine LactMed: Promethazine
• DEA Drug Take-Back Program
• Poison Control Center

Conclusion: Informed Prescribing Is the Only Defensible Standard

Promethazine DM Cough Syrup occupies a specific, evidence-supported niche in antitussive pharmacotherapy: non-opioid, dual-mechanism symptomatic relief of dry, non-productive cough with a concurrent allergic or histaminergic component, in patients 2 years and older for whom the clinical indication is clear and the interaction risk has been fully assessed.

Its absence of opioid content removes codeine-specific risks: DEA scheduling obligations, the pediatric under-12 contraindication, CYP2D6-mediated morphine overproduction, and opioid use disorder potential. These are genuine clinical advantages in a prescribing landscape where minimizing opioid exposure is both a regulatory priority and an evidence-based clinical goal.

What Promethazine DM Cough Syrup retains—and what must not be minimized by its non-controlled status—is a pharmacological profile that demands the same clinical deliberateness as any sedating prescription medication. Promethazine produces real CNS depression, documented QT prolongation, meaningful anticholinergic burden in vulnerable populations, and pharmacodynamic risks that can produce fatal outcomes in children under 2 and life-threatening serotonin syndrome in patients receiving concurrent serotonergic medications.

Dextromethorphan is a serotonergic NMDA antagonist with documented misuse potential and pharmacokinetic variability that is pharmacogenomically determined and clinically unpredictable without CYP2D6 testing. Neither ingredient is pharmacologically simple. Neither can be safely prescribed without the individualized clinical assessment, complete medication reconciliation, patient education, and defined short-term treatment plan that the prescription requirement reflects.

Understanding what Promethazine DM treats and what it cannot treat, what Promethazine DM side effects require active monitoring, what Promethazine DM interactions demand contraindication, how Promethazine DM dosage must be precisely measured, how Promethazine DM compares to codeine-containing formulations and to benzonatate—this is the clinical literacy that every prescriber and pharmacist handling this medication is ethically and professionally obligated to maintain.

In antitussive pharmacotherapy, as in every corner of prescription medicine, the standard is not the absence of serious risk. It is the informed management of risk that a prescription authorization represents and a clinical relationship sustains.

This article is intended for informational purposes only and does not constitute medical advice, clinical guidance, or a recommendation for any specific treatment. Promethazine DM Cough Syrup is a prescription medication requiring physician authorization and clinical oversight. All treatment decisions should be made in consultation with a qualified, licensed healthcare professional. Content is reviewed for clinical accuracy and updated as the evidence base evolves.